Therapeutic effect of microRNA-21 on differentially expressed hub genes in gastric cancer based on systems biology

Hesam Ghafouri Kalajahi1, AmirHossein Yari2, Mohammad Amini2

  • 1Department of Molecular Biology and Genetics, Uskudar University, Uskudar, 34662, Istanbul, Turkey.

Scientific Reports
|December 11, 2023
PubMed

Insights

MicroRNA-21 (miR-21) drives gastric cancer (GC) by downregulating CCL28, NR3C2, and SNYPO2. Suppressing miR-21 inhibits GC cell growth and these key genes, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gastric cancer (GC) is a significant global health concern with poorly understood initiation factors.
  • MicroRNA-21 (miR-21) plays a critical role in the development and progression of various cancers, including GC.

Purpose of the Study:

  • To identify novel genes associated with miR-21 activity in GC.
  • To investigate the impact of miR-21 downregulation on these target genes and gastric tumorigenesis.
  • To explore potential therapeutic and diagnostic targets for GC.

Main Methods:

  • Utilized Gene Expression Omnibus (GEO) dataset (GSE13911) for differential gene expression analysis.
  • Employed Weighted Gene Correlation Network Analysis (WGCNA) to reconstruct gene co-expression networks.
  • Integrated miRWalk database for microRNA-mRNA network analysis and identified miR-21 targets.
  • Performed in vitro experiments using GC cell lines (MKN, AGS) with anti-miR-21 transfection, MTT assays, and qRT-PCR.

Main Results:

  • Identified CCL28, NR3C2, and SNYPO2 as novel targets of miR-21 in GC, which are downregulated during tumorigenesis.
  • Demonstrated that miR-21 suppression in GC cells inhibits cell proliferation.
  • Confirmed decreased expression of CCL28, NR3C2, and SNYPO2 following miR-21 downregulation.

Conclusions:

  • miR-21 significantly contributes to GC development by downregulating CCL28, NR3C2, and SNYPO2.
  • CCL28, NR3C2, and SNYPO2 show potential as diagnostic and therapeutic targets for gastric cancer surveillance and treatment.